PL3722291T3 - Związki indolinonowe i ich zastosowanie w leczeniu chorób zwłóknieniowych - Google Patents

Związki indolinonowe i ich zastosowanie w leczeniu chorób zwłóknieniowych

Info

Publication number
PL3722291T3
PL3722291T3 PL20162043.2T PL20162043T PL3722291T3 PL 3722291 T3 PL3722291 T3 PL 3722291T3 PL 20162043 T PL20162043 T PL 20162043T PL 3722291 T3 PL3722291 T3 PL 3722291T3
Authority
PL
Poland
Prior art keywords
treatment
fibrotic diseases
indolinone compounds
indolinone
compounds
Prior art date
Application number
PL20162043.2T
Other languages
English (en)
Inventor
Iain Walters
Louise BIRCH
Joseph HILL-COUSINS
Stephen Paul Collingwood
Christopher Scott Stevenson
Original Assignee
Respivert Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Respivert Limited filed Critical Respivert Limited
Publication of PL3722291T3 publication Critical patent/PL3722291T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL20162043.2T 2015-12-24 2016-12-23 Związki indolinonowe i ich zastosowanie w leczeniu chorób zwłóknieniowych PL3722291T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15202764 2015-12-24

Publications (1)

Publication Number Publication Date
PL3722291T3 true PL3722291T3 (pl) 2023-11-27

Family

ID=55068868

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20162043.2T PL3722291T3 (pl) 2015-12-24 2016-12-23 Związki indolinonowe i ich zastosowanie w leczeniu chorób zwłóknieniowych

Country Status (30)

Country Link
US (1) US11046672B2 (pl)
EP (2) EP3722291B1 (pl)
JP (1) JP7068172B2 (pl)
KR (1) KR20180128390A (pl)
CN (1) CN109302846B (pl)
AU (1) AU2016376011B2 (pl)
BR (1) BR112018013033A2 (pl)
CA (1) CA3009778A1 (pl)
CL (1) CL2018001742A1 (pl)
CO (1) CO2018007663A2 (pl)
CY (1) CY1126258T1 (pl)
DK (1) DK3722291T3 (pl)
EA (1) EA038796B1 (pl)
ES (2) ES2796358T3 (pl)
FI (1) FI3722291T3 (pl)
HR (1) HRP20230833T1 (pl)
HU (1) HUE062784T2 (pl)
IL (1) IL260221A (pl)
LT (1) LT3722291T (pl)
MX (1) MX379859B (pl)
MY (1) MY195904A (pl)
PH (1) PH12018501575A1 (pl)
PL (1) PL3722291T3 (pl)
PT (1) PT3722291T (pl)
RS (1) RS64703B1 (pl)
SG (1) SG11201805423TA (pl)
SI (1) SI3722291T1 (pl)
SM (1) SMT202300260T1 (pl)
WO (1) WO2017109513A1 (pl)
ZA (1) ZA201804950B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3066112T3 (en) 2015-12-24 2026-05-11 The Regents Of The Univ Of California Cftr regulators and methods of use thereof
JP7039480B2 (ja) * 2016-03-08 2022-03-22 レスピバート・リミテツド プロテインキナーゼ阻害剤としてのインドール誘導体およびそれらの使用
EP3672598A4 (en) 2017-08-24 2021-04-28 The Regents of The University of California OCULAR PHARMACEUTICAL COMPOSITIONS
CN109678810B (zh) * 2019-01-23 2022-10-28 南京工业大学 一种1,2-氧氮杂环丁烷类化合物及其制备方法与应用
AU2020386913A1 (en) * 2019-11-20 2022-06-02 Angion Biomedica Corp. Methods for treating inflammatory bowel disease
CN111789842B (zh) * 2020-08-07 2021-09-21 南开大学 尼达尼布在制备用于治疗炎症性肠病的药物中的应用
KR102739882B1 (ko) * 2021-04-02 2024-12-06 연세대학교 원주산학협력단 로베글리타존을 유효성분으로 하는 안과질환 치료용 조성물
CN113200936B (zh) * 2021-05-19 2022-10-21 南京工业大学 10-甲基吩噁嗪衍生物、其锆金属有机框架材料及制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE10117204A1 (de) * 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
JP2004182726A (ja) 2002-11-22 2004-07-02 Yamanouchi Pharmaceut Co Ltd 2−オキソインドリン誘導体
US20060154939A1 (en) * 2004-12-24 2006-07-13 Boehringer Ingelheim International Gmbh Medicaments for the Treatment or Prevention of Fibrotic Diseases
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1902025A1 (en) * 2005-07-13 2008-03-26 Allergan, Inc. Kinase inhibitors
CA2728228A1 (en) * 2008-07-14 2010-01-21 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
JP7039480B2 (ja) 2016-03-08 2022-03-22 レスピバート・リミテツド プロテインキナーゼ阻害剤としてのインドール誘導体およびそれらの使用

Also Published As

Publication number Publication date
HRP20230833T1 (hr) 2023-11-10
CN109302846B (zh) 2021-05-11
EA201891506A1 (ru) 2019-02-28
CL2018001742A1 (es) 2018-11-23
SG11201805423TA (en) 2018-07-30
DK3722291T3 (da) 2023-09-18
IL260221A (en) 2018-07-31
HUE062784T2 (hu) 2023-12-28
JP2019501910A (ja) 2019-01-24
EP3394048B1 (en) 2020-03-11
MX379859B (es) 2025-03-11
EP3722291A1 (en) 2020-10-14
MX2018007852A (es) 2018-11-09
ES2796358T3 (es) 2020-11-26
SMT202300260T1 (it) 2023-09-06
FI3722291T3 (fi) 2023-09-05
US11046672B2 (en) 2021-06-29
ES2956820T3 (es) 2023-12-28
MY195904A (en) 2023-02-27
AU2016376011A1 (en) 2018-08-09
SI3722291T1 (sl) 2023-10-30
EP3394048A1 (en) 2018-10-31
PH12018501575A1 (en) 2019-04-15
US20190337929A1 (en) 2019-11-07
EP3722291B1 (en) 2023-07-19
RS64703B1 (sr) 2023-11-30
EA038796B1 (ru) 2021-10-20
AU2016376011B2 (en) 2021-02-11
KR20180128390A (ko) 2018-12-03
PT3722291T (pt) 2023-09-22
WO2017109513A1 (en) 2017-06-29
CY1126258T1 (el) 2026-02-25
LT3722291T (lt) 2023-12-11
CO2018007663A2 (es) 2018-10-10
CN109302846A (zh) 2019-02-01
BR112018013033A2 (pt) 2018-12-04
ZA201804950B (en) 2020-11-25
JP7068172B2 (ja) 2022-05-16
CA3009778A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
GB201403093D0 (en) Therapeutic compounds and their use
IL248326B (en) A dimer of buprenorphine and its use in the treatment of diseases of the stomach and intestines
ZA201804950B (en) Indolinones compounds and their use in the treatment of fibrotic diseases
IL249458A0 (en) ppar compounds for use in the treatment of fibrotic diseases
EP3130582B8 (en) Compound having immune disease treatment effect and use thereof
GB201404403D0 (en) Compositions and methods relating to the treatment of diseases
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
GB201617064D0 (en) Compounds and their therapeutic use
ZA201802134B (en) Therapeutic compounds and methods of use thereof
IL258316A (en) A combination of trazodone and gabapentin for the treatment of pain
IL251135A (en) A method for the synthesis of hydroxy-triglycerides and their use for disease prevention and treatment
SG11201701618SA (en) Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
HK1263136A1 (en) Indolinones compounds and their use in the treatment of fibrotic diseases
IL250244B (en) Prevention and treatment of inflammatory skin diseases
GB201410387D0 (en) Compounds and their therapeutic use
GB201403496D0 (en) Compounds and their therapeutic use
HK1248110A1 (en) Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases
GB201409978D0 (en) Novel compounds and their use in therapy